Review



nanocomposites  (Hitachi Ltd)


Bioz Verified Symbol Hitachi Ltd is a verified supplier
Bioz Manufacturer Symbol Hitachi Ltd manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Hitachi Ltd nanocomposites
    Nanocomposites, supplied by Hitachi Ltd, used in various techniques. Bioz Stars score: 96/100, based on 897 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nanocomposites/10__1007_slash_s10971___026___07165___5-82-6-11?v=Hitachi+Ltd
    Average 96 stars, based on 897 article reviews
    nanocomposites - by Bioz Stars, 2026-08
    96/100 stars

    Images



    Similar Products

    86
    Accelrys nanocomposites
    Nanocomposites, supplied by Accelrys, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nanocomposites/pm42286162-433-0-2?v=Accelrys
    Average 86 stars, based on 1 article reviews
    nanocomposites - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    86
    Photonics Inc block copolymer nanocomposites
    Block Copolymer Nanocomposites, supplied by Photonics Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nanocomposites/pm42263146-211-0-10?v=Photonics+Inc
    Average 86 stars, based on 1 article reviews
    block copolymer nanocomposites - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    86
    Medicago nanocomposite treatment increased bcf values for mn
    Nanocomposite Treatment Increased Bcf Values For Mn, supplied by Medicago, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nanocomposites/pm42250851-294-9-5?v=Medicago
    Average 86 stars, based on 1 article reviews
    nanocomposite treatment increased bcf values for mn - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    86
    Molecular Dynamics Inc nanocomposite synthesis
    Physicochemical characterization of the Se–Ag/chitosan hybrid <t>nanocomposite.</t>
    Nanocomposite Synthesis, supplied by Molecular Dynamics Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nanocomposites/pmc13245370-504-7-13?v=Molecular+Dynamics+Inc
    Average 86 stars, based on 1 article reviews
    nanocomposite synthesis - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    86
    Vitex Inc cuo c nanocomposites
    Physicochemical characterization of the Se–Ag/chitosan hybrid <t>nanocomposite.</t>
    Cuo C Nanocomposites, supplied by Vitex Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nanocomposites/pm42185337-895-18-22?v=Vitex+Inc
    Average 86 stars, based on 1 article reviews
    cuo c nanocomposites - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    99
    JEOL pvp cmc cnt nanocomposite hydrogel
    Physicochemical characterization of the Se–Ag/chitosan hybrid <t>nanocomposite.</t>
    Pvp Cmc Cnt Nanocomposite Hydrogel, supplied by JEOL, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nanocomposites/pm42098741-98-9-16?v=JEOL
    Average 99 stars, based on 1 article reviews
    pvp cmc cnt nanocomposite hydrogel - by Bioz Stars, 2026-08
    99/100 stars
      Buy from Supplier

    86
    Postbiotics Inc cs alg cur postbiotics nanocomposite
    Physicochemical characterization of the Se–Ag/chitosan hybrid <t>nanocomposite.</t>
    Cs Alg Cur Postbiotics Nanocomposite, supplied by Postbiotics Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nanocomposites/10__1016_slash_j__fbio__2026__109116-185-5-5?v=Postbiotics+Inc
    Average 86 stars, based on 1 article reviews
    cs alg cur postbiotics nanocomposite - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    99
    JEOL jem-2100 transmission electron microscope
    Physicochemical characterization of the Se–Ag/chitosan hybrid <t>nanocomposite.</t>
    Jem 2100 Transmission Electron Microscope, supplied by JEOL, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nanocomposites/custom%40jem-2100%4042032327?v=JEOL
    Average 99 stars, based on 1 article reviews
    jem-2100 transmission electron microscope - by Bioz Stars, 2026-08
    99/100 stars
      Buy from Supplier

    96
    Hitachi Ltd nanocomposites
    Physicochemical characterization of the Se–Ag/chitosan hybrid <t>nanocomposite.</t>
    Nanocomposites, supplied by Hitachi Ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nanocomposites/10__1007_slash_s10971___026___07165___5-82-6-11?v=Hitachi+Ltd
    Average 96 stars, based on 1 article reviews
    nanocomposites - by Bioz Stars, 2026-08
    96/100 stars
      Buy from Supplier

    Image Search Results


    Physicochemical characterization of the Se–Ag/chitosan hybrid nanocomposite.

    Journal: RSC Advances

    Article Title: Chitosan-confined selenium–silver nanohybrids enable redox-modulated mitochondrial apoptosis and survival improvement in experimental hepatocellular carcinoma

    doi: 10.1039/d6ra01968d

    Figure Lengend Snippet: Physicochemical characterization of the Se–Ag/chitosan hybrid nanocomposite.

    Article Snippet: Youssef M. Hassan: Performed all experimental work, nanocomposite synthesis, computational modeling (quantum chemistry, molecular dynamics, PBPK, systems biology, machine learning), data analysis, and manuscript writing.

    Techniques:

    Survival analysis demonstrating the protective effect of Se/Ag chitosan nanocomposite treatment in diethylnitrosamine-induced hepatocellular carcinoma. (A) Kaplan–Meier survival curves showing survival probability over the 14 weeks experimental period. Control and Se/Ag alone groups maintained 100% survival. Early HCC and Late HCC groups exhibited progressive mortality with final survival rates of 55% and 20%, respectively. Treatment with Se/Ag nanocomposite significantly improved survival outcomes in both earlystage (85% survival) and late-stage (70% survival) HCC groups compared to their respective untreated counterparts. (B) Bar graph depicting final survival rates at the experimental endpoint (week 14). The graph demonstrates complete survival in control and Se/Ag alone groups, severe mortality in untreated HCC groups (particularly late-stage HCC at 20%), and substantial protective effects of Se/Ag treatment in both HCC progression stages. (C) Cumulative mortality curves illustrating the temporal progression of death events. Late HCC group showed the earliest and steepest mortality increase, while Se/Ag treatment significantly delayed and reduced cumulative mortality in both HCC groups throughout the observation period. (D) Statistical comparison table presenting log-rank test results for key group comparisons. All comparisons between HCC groups and controls, as well as between treated and untreated HCC groups, showed highly significant differences ( p < 0.01 to p < 0.0001).

    Journal: RSC Advances

    Article Title: Chitosan-confined selenium–silver nanohybrids enable redox-modulated mitochondrial apoptosis and survival improvement in experimental hepatocellular carcinoma

    doi: 10.1039/d6ra01968d

    Figure Lengend Snippet: Survival analysis demonstrating the protective effect of Se/Ag chitosan nanocomposite treatment in diethylnitrosamine-induced hepatocellular carcinoma. (A) Kaplan–Meier survival curves showing survival probability over the 14 weeks experimental period. Control and Se/Ag alone groups maintained 100% survival. Early HCC and Late HCC groups exhibited progressive mortality with final survival rates of 55% and 20%, respectively. Treatment with Se/Ag nanocomposite significantly improved survival outcomes in both earlystage (85% survival) and late-stage (70% survival) HCC groups compared to their respective untreated counterparts. (B) Bar graph depicting final survival rates at the experimental endpoint (week 14). The graph demonstrates complete survival in control and Se/Ag alone groups, severe mortality in untreated HCC groups (particularly late-stage HCC at 20%), and substantial protective effects of Se/Ag treatment in both HCC progression stages. (C) Cumulative mortality curves illustrating the temporal progression of death events. Late HCC group showed the earliest and steepest mortality increase, while Se/Ag treatment significantly delayed and reduced cumulative mortality in both HCC groups throughout the observation period. (D) Statistical comparison table presenting log-rank test results for key group comparisons. All comparisons between HCC groups and controls, as well as between treated and untreated HCC groups, showed highly significant differences ( p < 0.01 to p < 0.0001).

    Article Snippet: Youssef M. Hassan: Performed all experimental work, nanocomposite synthesis, computational modeling (quantum chemistry, molecular dynamics, PBPK, systems biology, machine learning), data analysis, and manuscript writing.

    Techniques: Control, Comparison

    Biochemical, inflammatory, and multivariate assessment of therapeutic response to Se–Ag–CS nanocomposites in hepatocellular carcinoma. (A) Serum liver enzyme activities (ALT, AST, and ALP) across healthy, HCC, early-treatment (Early Tx), and late-treatment (Late Tx) groups, showing significant enzyme elevation in HCC and partial to substantial normalization following treatment. (B) Oxidative stress markers, malondialdehyde (MDA) and reduced glutathione (GSH), indicating pronounced oxidative imbalance in HCC and restoration toward redox homeostasis after therapy. (C) Pro-inflammatory cytokines TNF-α and IL-6, markedly elevated in HCC and significantly reduced upon treatment, with greater suppression in early intervention. (D) Serum alpha-fetoprotein (AFP) levels relative to the clinical threshold, demonstrating strong AFP reduction following treatment, particularly in the early-treatment group. (E) Superoxide dismutase (SOD) activity, reflecting impaired antioxidant defense in HCC and recovery after nanocomposite administration. (F) Oxidative stress index (OSI; MDA/GSH × 100), summarizing redox imbalance and highlighting effective oxidative stress mitigation with treatment. (G) Therapeutic efficacy quantified by AFP reduction, showing superior response in early-stage HCC compared with late-stage disease. (H) Multi-biomarker efficacy analysis illustrating coordinated reductions in liver enzymes and inflammatory cytokines, with enhanced benefit in early HCC. (I) Principal component analysis (PCA) integrating all biomarkers, demonstrating clear separation between healthy, HCC, and treated groups, and confirming systemic biochemical normalization following Se–Ag–CS nanocomposite therapy.

    Journal: RSC Advances

    Article Title: Chitosan-confined selenium–silver nanohybrids enable redox-modulated mitochondrial apoptosis and survival improvement in experimental hepatocellular carcinoma

    doi: 10.1039/d6ra01968d

    Figure Lengend Snippet: Biochemical, inflammatory, and multivariate assessment of therapeutic response to Se–Ag–CS nanocomposites in hepatocellular carcinoma. (A) Serum liver enzyme activities (ALT, AST, and ALP) across healthy, HCC, early-treatment (Early Tx), and late-treatment (Late Tx) groups, showing significant enzyme elevation in HCC and partial to substantial normalization following treatment. (B) Oxidative stress markers, malondialdehyde (MDA) and reduced glutathione (GSH), indicating pronounced oxidative imbalance in HCC and restoration toward redox homeostasis after therapy. (C) Pro-inflammatory cytokines TNF-α and IL-6, markedly elevated in HCC and significantly reduced upon treatment, with greater suppression in early intervention. (D) Serum alpha-fetoprotein (AFP) levels relative to the clinical threshold, demonstrating strong AFP reduction following treatment, particularly in the early-treatment group. (E) Superoxide dismutase (SOD) activity, reflecting impaired antioxidant defense in HCC and recovery after nanocomposite administration. (F) Oxidative stress index (OSI; MDA/GSH × 100), summarizing redox imbalance and highlighting effective oxidative stress mitigation with treatment. (G) Therapeutic efficacy quantified by AFP reduction, showing superior response in early-stage HCC compared with late-stage disease. (H) Multi-biomarker efficacy analysis illustrating coordinated reductions in liver enzymes and inflammatory cytokines, with enhanced benefit in early HCC. (I) Principal component analysis (PCA) integrating all biomarkers, demonstrating clear separation between healthy, HCC, and treated groups, and confirming systemic biochemical normalization following Se–Ag–CS nanocomposite therapy.

    Article Snippet: Youssef M. Hassan: Performed all experimental work, nanocomposite synthesis, computational modeling (quantum chemistry, molecular dynamics, PBPK, systems biology, machine learning), data analysis, and manuscript writing.

    Techniques: Clinical Proteomics, Activity Assay, Drug discovery, Biomarker Discovery

    Multiscale pharmacokinetic–pharmacodynamic and therapeutic response modeling of green-synthesized Se–Ag–CS nanocomposites in hepatocellular carcinoma. Simulated plasma and peripheral tissue concentration–time profiles following systemic administration illustrate rapid absorption, systemic distribution, and sustained exposure above the effective concentration threshold. Hepatic accumulation kinetics demonstrate preferential liver targeting and prolonged retention relative to plasma, with stage-specific effective concentration (EC 50 ) thresholds distinguishing early and late hepatocellular carcinoma (HCC). Concentration–response relationships link nanocomposite exposure to tumor cell kill, highlighting enhanced therapeutic sensitivity in early-stage HCC compared with advanced disease. Time-dependent pharmacodynamic modeling further confirms sustained antitumor activity, with reduced efficacy observed in late-stage HCC. Alpha-fetoprotein (AFP) dynamics serve as a biomarker of therapeutic response, showing marked suppression under early treatment conditions relative to late treatment and untreated controls. Liver enzyme normalization profiles ALT and AST indicate transient treatment-associated perturbations followed by recovery toward physiological ranges, supporting a favorable hepatic safety profile. Tumor growth inhibition modeling over a 30 days period demonstrates significant regression with early intervention and growth stabilization under late treatment compared with unchecked progression in untreated tumors. Key pharmacokinetic parameters—including maximum concentration ( C _max), time to peak concentration ( T _max), area under the curve (AUC), clearance, mean residence time, and liver targeting index—quantitatively support enhanced hepatic delivery efficiency and therapeutic performance of the Se–Ag–CS nanocomposites.

    Journal: RSC Advances

    Article Title: Chitosan-confined selenium–silver nanohybrids enable redox-modulated mitochondrial apoptosis and survival improvement in experimental hepatocellular carcinoma

    doi: 10.1039/d6ra01968d

    Figure Lengend Snippet: Multiscale pharmacokinetic–pharmacodynamic and therapeutic response modeling of green-synthesized Se–Ag–CS nanocomposites in hepatocellular carcinoma. Simulated plasma and peripheral tissue concentration–time profiles following systemic administration illustrate rapid absorption, systemic distribution, and sustained exposure above the effective concentration threshold. Hepatic accumulation kinetics demonstrate preferential liver targeting and prolonged retention relative to plasma, with stage-specific effective concentration (EC 50 ) thresholds distinguishing early and late hepatocellular carcinoma (HCC). Concentration–response relationships link nanocomposite exposure to tumor cell kill, highlighting enhanced therapeutic sensitivity in early-stage HCC compared with advanced disease. Time-dependent pharmacodynamic modeling further confirms sustained antitumor activity, with reduced efficacy observed in late-stage HCC. Alpha-fetoprotein (AFP) dynamics serve as a biomarker of therapeutic response, showing marked suppression under early treatment conditions relative to late treatment and untreated controls. Liver enzyme normalization profiles ALT and AST indicate transient treatment-associated perturbations followed by recovery toward physiological ranges, supporting a favorable hepatic safety profile. Tumor growth inhibition modeling over a 30 days period demonstrates significant regression with early intervention and growth stabilization under late treatment compared with unchecked progression in untreated tumors. Key pharmacokinetic parameters—including maximum concentration ( C _max), time to peak concentration ( T _max), area under the curve (AUC), clearance, mean residence time, and liver targeting index—quantitatively support enhanced hepatic delivery efficiency and therapeutic performance of the Se–Ag–CS nanocomposites.

    Article Snippet: Youssef M. Hassan: Performed all experimental work, nanocomposite synthesis, computational modeling (quantum chemistry, molecular dynamics, PBPK, systems biology, machine learning), data analysis, and manuscript writing.

    Techniques: Clinical Proteomics, Synthesized, Concentration Assay, Activity Assay, Biomarker Discovery, Inhibition

    Statistical, correlative, and predictive analysis of biomarker modulation following Se–Ag–CS nanocomposite therapy in hepatocellular carcinoma. (A) Biomarker correlation matrix illustrating strong positive associations among liver injury markers (ALT, AST, ALP, bilirubin), inflammatory cytokines (TNF-α, IL-6), oxidative stress indicators (MDA), and AFP, with pronounced negative correlations between antioxidant defenses (GSH, SOD) and pathological biomarkers, indicating coordinated disease-driven dysregulation. (B) One-way ANOVA statistical analysis confirming significant intergroup differences across all measured biomarkers, with highly significant F-statistics and p -values supporting robust treatment effects. (C) Distribution of serum AFP levels across healthy, HCC, early-treatment, and late-treatment groups, demonstrating marked elevation in untreated HCC and substantial reduction following therapy, particularly with early intervention. (D) Projected AFP time-course profiles over 14 days, showing progressive AFP increase in untreated tumors, accelerated decline with early treatment, and partial response under late treatment relative to the normal reference range. (E) Comparative treatment efficacy based on percentage reduction of key biomarkers (ALT, AST, AFP, and TNF-α), highlighting superior therapeutic benefit in early-stage HCC compared with late-stage disease.

    Journal: RSC Advances

    Article Title: Chitosan-confined selenium–silver nanohybrids enable redox-modulated mitochondrial apoptosis and survival improvement in experimental hepatocellular carcinoma

    doi: 10.1039/d6ra01968d

    Figure Lengend Snippet: Statistical, correlative, and predictive analysis of biomarker modulation following Se–Ag–CS nanocomposite therapy in hepatocellular carcinoma. (A) Biomarker correlation matrix illustrating strong positive associations among liver injury markers (ALT, AST, ALP, bilirubin), inflammatory cytokines (TNF-α, IL-6), oxidative stress indicators (MDA), and AFP, with pronounced negative correlations between antioxidant defenses (GSH, SOD) and pathological biomarkers, indicating coordinated disease-driven dysregulation. (B) One-way ANOVA statistical analysis confirming significant intergroup differences across all measured biomarkers, with highly significant F-statistics and p -values supporting robust treatment effects. (C) Distribution of serum AFP levels across healthy, HCC, early-treatment, and late-treatment groups, demonstrating marked elevation in untreated HCC and substantial reduction following therapy, particularly with early intervention. (D) Projected AFP time-course profiles over 14 days, showing progressive AFP increase in untreated tumors, accelerated decline with early treatment, and partial response under late treatment relative to the normal reference range. (E) Comparative treatment efficacy based on percentage reduction of key biomarkers (ALT, AST, AFP, and TNF-α), highlighting superior therapeutic benefit in early-stage HCC compared with late-stage disease.

    Article Snippet: Youssef M. Hassan: Performed all experimental work, nanocomposite synthesis, computational modeling (quantum chemistry, molecular dynamics, PBPK, systems biology, machine learning), data analysis, and manuscript writing.

    Techniques: Biomarker Discovery

    Histopathological and immunohistochemical evaluation of HCC and therapeutic response to Se–Ag/chitosan nanocomposite treatment. (A) Preservation of hepatic tissue architecture (% normal structure). Nanocomposite treatment substantially preserved liver architecture compared with untreated early and late HCC. (B) Inflammatory infiltration scored on a 0–10 scale, indicating reduced immune cell infiltration in treated groups. (C) Hepatic tissue necrosis (% area), showing marked attenuation following treatment. (D) Overall HCC severity score combining architectural disruption, necrosis, and inflammation. (E) p53 immunoexpression levels (% positive cells and intensity), demonstrating enhanced apoptotic signaling in treated tumors. (F) Ki-67 proliferation index (% positive cells), illustrating suppressed tumor proliferation posttreatment. (G) Correlation between proliferation and apoptosis indices, highlighting treatment-induced shift toward apoptosis in both early and late HCC. (H) Histological treatment response score (% improvement relative to untreated HCC), with higher efficacy in early intervention. (I) Radar plot summarizing multiple histological features (architecture, hepatocyte integrity, sinusoidal structure), showing normalization trends in treated livers. (J) Heatmap of normalized histopathological features across groups, illustrating treatmentmediated modulation of proliferation, apoptosis, inflammation, and necrosis. All data represent mean ± SD. Statistical significance: p < 0.05, p < 0.01, p < 0.001.

    Journal: RSC Advances

    Article Title: Chitosan-confined selenium–silver nanohybrids enable redox-modulated mitochondrial apoptosis and survival improvement in experimental hepatocellular carcinoma

    doi: 10.1039/d6ra01968d

    Figure Lengend Snippet: Histopathological and immunohistochemical evaluation of HCC and therapeutic response to Se–Ag/chitosan nanocomposite treatment. (A) Preservation of hepatic tissue architecture (% normal structure). Nanocomposite treatment substantially preserved liver architecture compared with untreated early and late HCC. (B) Inflammatory infiltration scored on a 0–10 scale, indicating reduced immune cell infiltration in treated groups. (C) Hepatic tissue necrosis (% area), showing marked attenuation following treatment. (D) Overall HCC severity score combining architectural disruption, necrosis, and inflammation. (E) p53 immunoexpression levels (% positive cells and intensity), demonstrating enhanced apoptotic signaling in treated tumors. (F) Ki-67 proliferation index (% positive cells), illustrating suppressed tumor proliferation posttreatment. (G) Correlation between proliferation and apoptosis indices, highlighting treatment-induced shift toward apoptosis in both early and late HCC. (H) Histological treatment response score (% improvement relative to untreated HCC), with higher efficacy in early intervention. (I) Radar plot summarizing multiple histological features (architecture, hepatocyte integrity, sinusoidal structure), showing normalization trends in treated livers. (J) Heatmap of normalized histopathological features across groups, illustrating treatmentmediated modulation of proliferation, apoptosis, inflammation, and necrosis. All data represent mean ± SD. Statistical significance: p < 0.05, p < 0.01, p < 0.001.

    Article Snippet: Youssef M. Hassan: Performed all experimental work, nanocomposite synthesis, computational modeling (quantum chemistry, molecular dynamics, PBPK, systems biology, machine learning), data analysis, and manuscript writing.

    Techniques: Immunohistochemical staining, Clinical Proteomics, Preserving, Disruption

    Multiscale computational framework elucidating the physicochemical and biological mechanisms of Se–Ag chitosan nanocomposites in hepatocellular carcinoma therapy. (A) Representative molecular dynamics trajectory (5 ns, 80 atoms) showing structural stability of Se–Ag nanocomposites. (B) Energy conservation profile illustrating stable kinetic, potential, and total energies over the simulation time. (C) Temperature equilibration under Berendsen thermostat control at 310 K. (D) Radial distribution function (RDF) highlighting preferential interatomic distances and structural ordering. (E) Potential of mean force (PMF) depicting the thermodynamic favorability of nanoparticle–protein interactions. (F) Summary of binding parameters, including optimal distance and dissociation constant, confirming strong electrostatic and van der Waals contributions. (G) Dose-dependent kinetics of reactive oxygen species (ROS) generation. (H) Time-dependent glutathione (GSH) depletion indicating tumor-selective oxidative stress. (I) Quantum confinement effect on band gap energy as a function of nanoparticle radius. (J) Size-dependent work function variation. (K) Optical absorption properties across UV-visible spectra. (L) Density of states (DOS) illustrating size-dependent electronic structure modulation. (M) Langmuir adsorption isotherm describing nanoparticle–surface interactions. (N) Surface reaction kinetics based on the Langmuir–Hinshelwood model. (O) Arrhenius plot showing temperature dependence of reaction rate constants. (P) Pourbaix diagram indicating pH-dependent selenium speciation and thermodynamic stability under physiological conditions.

    Journal: RSC Advances

    Article Title: Chitosan-confined selenium–silver nanohybrids enable redox-modulated mitochondrial apoptosis and survival improvement in experimental hepatocellular carcinoma

    doi: 10.1039/d6ra01968d

    Figure Lengend Snippet: Multiscale computational framework elucidating the physicochemical and biological mechanisms of Se–Ag chitosan nanocomposites in hepatocellular carcinoma therapy. (A) Representative molecular dynamics trajectory (5 ns, 80 atoms) showing structural stability of Se–Ag nanocomposites. (B) Energy conservation profile illustrating stable kinetic, potential, and total energies over the simulation time. (C) Temperature equilibration under Berendsen thermostat control at 310 K. (D) Radial distribution function (RDF) highlighting preferential interatomic distances and structural ordering. (E) Potential of mean force (PMF) depicting the thermodynamic favorability of nanoparticle–protein interactions. (F) Summary of binding parameters, including optimal distance and dissociation constant, confirming strong electrostatic and van der Waals contributions. (G) Dose-dependent kinetics of reactive oxygen species (ROS) generation. (H) Time-dependent glutathione (GSH) depletion indicating tumor-selective oxidative stress. (I) Quantum confinement effect on band gap energy as a function of nanoparticle radius. (J) Size-dependent work function variation. (K) Optical absorption properties across UV-visible spectra. (L) Density of states (DOS) illustrating size-dependent electronic structure modulation. (M) Langmuir adsorption isotherm describing nanoparticle–surface interactions. (N) Surface reaction kinetics based on the Langmuir–Hinshelwood model. (O) Arrhenius plot showing temperature dependence of reaction rate constants. (P) Pourbaix diagram indicating pH-dependent selenium speciation and thermodynamic stability under physiological conditions.

    Article Snippet: Youssef M. Hassan: Performed all experimental work, nanocomposite synthesis, computational modeling (quantum chemistry, molecular dynamics, PBPK, systems biology, machine learning), data analysis, and manuscript writing.

    Techniques: Control, Binding Assay, Adsorption